[1] |
Hakim A, Cooke KR, Pavletic SZ, et al. Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally[J]. Bone Marrow Transplant, 2019, 54(3):383-392.
doi: 10.1038/s41409-018-0266-6
|
[2] |
Kulkarni HS, Cherikh WS, Chambers DC, et al. Bronchiolitis obliterans syndrome—free survival after lung transplantation[J]. J Heart Lung Transplant, 2019, 38(1):5-16.
doi: 10.1016/j.healun.2018.09.016
URL
|
[3] |
Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment[J]. J Heart Lung Transplant, 2019, 38(5):493-503.
doi: 10.1016/j.healun.2019.03.009
URL
|
[4] |
Abedin S, Yanik GA, Braun T, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung[J]. Biol Blood Marrow Transplant, 2015, 21(6):1127-1131.
doi: 10.1016/j.bbmt.2015.02.006
URL
|
[5] |
Driskel M, Horsley A, Fretwell L, et al. Lung clearance index in detection of post-transplant bronchiolitis obliterans syndrome[J]. ERJ Open Res, 2019, 5(4):00164-2019.
|
[6] |
Nishimoto K, Karayama M, Inui N, et al. Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma[J]. Sci Rep, 2017, 7(1):10187.
doi: 10.1038/s41598-017-10504-w
pmid: 28860527
|
[7] |
Davidsen JR, Laursen CB, Højlund M, et al. Lung ultrasound to phenotype chronic lung allograft dysfunction in lung transplant recipients[J]. J Clin Med, 2021, 10(5):1078.
doi: 10.3390/jcm10051078
URL
|
[8] |
Bos S, Milross L, Filby AJ, et al. Immune processes in the pathogenesis of chronic lung allograft dysfunction[J]. Eur Respir Rev, 2022, 31(165):220060.
doi: 10.1183/16000617.0060-2022
URL
|
[9] |
Berastegui C, Gómez-Ollés S, Sánchez-Vidaurre S, et al. BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients[J]. Clin Transplant, 2017, 31(3):e12898.
|
[10] |
Nakashima M, Shinya T, Oto T, et al. Diagnostic value of ventilation/perfusion single-photon emission computed tomography/computed tomography for bronchiolitis obliterans syndrome in patients after lung transplantation[J]. Nucl Med Commun, 2019, 40(7):703-710.
doi: 10.1097/MNM.0000000000001021
pmid: 31022070
|
[11] |
Walkup LL, Myers K, El-Bietar J, et al. Xenon-129 MRI detects ventilation deficits in paediatric stem cell transplant patients unable to perform spirometry[J]. Eur Respir J, 2019, 53(5):1801779.
doi: 10.1183/13993003.01779-2018
URL
|
[12] |
Verleden SE, Gheysens O, Goffin KE, et al. Role of 18F-FDG PET/CT in restrictive allograft syndrome after lung transplantation[J]. Transplantation, 2019, 103(4):823-831.
doi: 10.1097/TP.0000000000002393
pmid: 30086092
|
[13] |
Shino MY, Li N, Todd JL, et al. Correlation between BAL CXCR3 chemokines and lung allograft histopathologies[J]. Am J Transplant, 2021, 21(10):3401-3410.
doi: 10.1111/ajt.16601
URL
|
[14] |
Itabashi Y, Ravichandran R, Bansal S, et al. Decline in club cell secretory proteins, exosomes induction and immune responses to lung self-antigens, Kα1 tubulin and collagen V, leading to chronic rejection after human lung transplantation[J]. Transplantation, 2021, 105(6):1337-1346.
doi: 10.1097/TP.0000000000003428
URL
|
[15] |
Berastegui C, Gómez-Ollés S, Mendoza-Valderrey A, et al. Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation[J]. PLoS One, 2020, 15(1):e0226488.
|
[16] |
Ohshimo S, Bonella F, Sommerwerck U, et al. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation[J]. J Heart Lung Transplant, 2011, 30(12):1374-1380.
doi: 10.1016/j.healun.2011.07.010
URL
|
[17] |
Winkler A, Kahnert K, Behr J, et al. Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation[J]. Respir Res, 2018, 19(1):171.
doi: 10.1186/s12931-018-0881-1
|
[18] |
Siddiqui AS, Kumar G, Majumdar T, et al. Association of methacholine challenge test with diagnosis of chronic lung allograft dysfunction in lung transplant patients[J]. Clin Transplant, 2018, 32(10):e13397.
|
[19] |
Bedair B, Hachem RR. Management of chronic rejection after lung transplantation[J]. J Thorac Dis, 2021, 13(11):6645-6653.
doi: 10.21037/jtd-2021-19
pmid: 34992842
|
[20] |
Hao X, Peng C, Lian W, et al. Effect of azithromycin on bronchiolitis obliterans syndrome in posttransplant recipients[J]. Medicine (Baltimore), 2022, 101(28):e29160.
|
[21] |
Federica M, Nadia S, Monica M, et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection[J]. Clin Transplant, 2011, 25(4):E381-E389.
|
[22] |
Mohseni R, Mahdavi Sharif P, Behfar M, et al. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)[J]. Stem Cell Res Ther, 2023, 14(1):256.
doi: 10.1186/s13287-023-03498-y
pmid: 37726865
|
[23] |
Keller CA, Gonwa TA, Hodge DO, et al. Feasibility, safety, and tolerance of mesenchymal stem cell therapy for obstructive chronic lung allograft dysfunction[J]. Stem Cells Transl Med, 2018, 7(2):161-167.
doi: 10.1002/sctm.17-0198
URL
|
[24] |
January SE, Fester KA, Bain KB, et al. Rabbit antithymocyte globulin for the treatment of chronic lung allograft dysfunction[J]. Clin Transplant, 2019, 33(10):e13708.
|
[25] |
Neurohr C, Kneidinger N, Ghiani A, et al. A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation[J]. Am J Transplant, 2022, 22(1):222-229.
doi: 10.1111/ajt.16858
URL
|
[26] |
Iacono A, Wijesinha M, Rajagopal K, et al. A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation[J]. ERJ Open Res, 2019, 5(4):00167-2019.
|
[27] |
Sahakijpijarn S, Moon C, Ma X, et al. Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations[J]. Int J Pharm, 2020, 586:119490.
doi: 10.1016/j.ijpharm.2020.119490
URL
|
[28] |
Lebeer M, Kaes J, Lambrech M, et al. Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation[J]. Transpl Int, 2020, 33(2):216-228.
doi: 10.1111/tri.v33.2
URL
|
[29] |
Geng-Cahuayme AAA, Sáez-Giménez B, Altabas-González M, et al. Efficacy and safety of total lymphoid irradiation in different chronic lung allograft dysfunction phenotypes[J]. Clin Transplant, 2023, 37(2):e14891.
|
[30] |
Benazzo A, Bagnera C, Ius F, et al. A European multi-center analysis of extracorporeal photopheresis as therapy for chronic lung allograft dysfunction[J]. Transpl Int, 2024, 36:11551.
doi: 10.3389/ti.2023.11551
URL
|
[31] |
Biswas Roy S, Panchanathan R, Walia R, et al. Lung retransplantation for chronic rejection[J]. Ann Thorac Surg, 2018, 105(1):221-227.
doi: 10.1016/j.athoracsur.2017.07.025
URL
|
[32] |
Ohsumi A, Tanaka S, Yamada Y, et al. Various combinations of living and deceased donors for lung retransplantation-a single institutional retrospective study[J]. Interdiscip Cardiovasc Thorac Surg, 2024, 38(1):ivae010.
|